A phase III study of Roxadustat for the treatment of anemia in patients with myelodysplastic syndromes (MDS)

Trial Profile

A phase III study of Roxadustat for the treatment of anemia in patients with myelodysplastic syndromes (MDS)

Planning
Phase of Trial: Phase III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Roxadustat (Primary)
  • Indications Anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors FibroGen
  • Most Recent Events

    • 09 May 2017 According to a FibroGen media release, the company received approval from FDA to conduct this trial. This trial is expected to initiate in the third quarter of 2017.
    • 31 Mar 2017 According to a FibroGen media release, the company anticipates initiating this trial in the first half of 2017.
    • 06 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top